Currency In USD
| Previous Close | 9.22 |
| Open | 9.1 |
| Day High | 9.21 |
| Day Low | 9.02 |
| 52-Week High | 21.95 |
| 52-Week Low | 4.85 |
| Volume | 29,255 |
| Average Volume | 33,227 |
| Market Cap | 36.69M |
| PE | -0.71 |
| EPS | -12.85 |
| Moving Average 50 Days | 9.14 |
| Moving Average 200 Days | 8.84 |
| Change | -0.15 |
Data not available
FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum
GlobeNewswire Inc.
Jan 07, 2026 12:30 PM GMT
Name change to Kyntra Bio reflects the newly sharpened focus of the Company on novel therapies with potential for outsized impact in oncology and rare diseaseKyntra Bio will begin trading on Nasdaq under the trading symbol “KYNB” effective January 8t
Roxadustat Granted Orphan Drug Designation for the Treatment of Myelodysplastic Syndromes by the U.S. Food and Drug Administration
GlobeNewswire Inc.
Dec 15, 2025 12:00 PM GMT
Company is on track to file the Phase 3 protocol in the fourth quarter of 2025 SAN FRANCISCO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Office of Orphan Products Development of the U.S. Food and Drug A
FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit
GlobeNewswire Inc.
Dec 02, 2025 9:05 PM GMT
SAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending and presenting at the Oppenheimer Movers in Rare Disease Summit being held on December 11, 2025, in New York, NY. Than